Center Point Clinical Services Signs Partnership Agreement with ContraVir Pharmaceuticals

MINNETONKA, Minnesota, June 29, 2016 /PRNewswire/ --

Center Point Clinical Services, provider of specialty clinical research solutions including the signature Clinical Trials Research Pharmacist (CTRP^®) solution, announced today that it is renewing its partnering agreement with ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies.  Under the terms of the agreement, Center Point will continue to provide its CTRP solution to support the clinical sites participating in ContraVir's Phase 3, randomized study of FV-100, in development as a fast-acting, low-dose, once-daily, oral antiviral therapy for the treatment of herpes zoster, or shingles.

     (Logo: http://photos.prnewswire.com/prnh/20160317/345390LOGO )

CTRP is an innovative patient engagement service offered only by Center Pont. It uses licensed, specially trained clinical pharmacists to communicate with study patients, the clinical sites, the CRO, and the study sponsor.  The CTRPs, all with expertise in clinical trials, drug issues, and patient counseling, engage patients at important stages of the trial to confirm study medication guidelines are clearly understood and being properly followed. All discussions between CTRPs and patients are documented and shared with the trial team. The CTRP solution has repeatedly demonstrated its ability to improve patient medication and device compliance, support patient retention, and enhance overall study outcomes.  

"ContraVir is taking every measure to make sure that the Phase 3 FV-100 study for shingles proceeds professionally and smoothly. Crystal clear communication amongst all involved is essential to achieving these goals and robust outcomes. Securing strong channels of communication and patient engagement are CTRP specialties. Center Point's capable, experienced and personable pharmacists prove their value daily.  The trial patients are more compliant because of their expertise and personal attention and the trial team is better informed and in a timely manner.  For these reasons, we are very pleased to be working with Center Point," said Terri Matkovits, Senior VP of Drug Development at ContraVir.

Shingles is an infection caused by the reactivation of the varicella zoster (chicken pox) virus.  

It is estimated that there are more than four million cases of shingles each year in the U.S., Europe, and Japan.  The symptoms associated with shingles generally include localized lesions and pain, generally burning sensations, with bouts of stabbing and shooting pain that can last as long as a month.

"We are delighted to continue our important partnership with ContraVir, a leader in the pharmaceutical industry, tirelessly working to bring effective anti-viral therapies to the market for conditions like shingles and hepatitis B. We are confident that the CTRP solution will continue to make a tremendous positive impact on the company's Phase 3 study by increasing patient compliance and creating an efficient information flow between the team.  Both will lead to reliable data for scientific publications and support future regulatory submissions," said Joe Martinez, CEO of Center Point.

About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead clinical drug, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development.  In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study.  ContraVir is also focused on developing its novel antiviral candidates for treating hepatitis B.  These include its Phase 2a clinical candidate CMX157, a novel, highly potent analog of the successful antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to Viread^® and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CPI-431-32, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.  

About Center Point Clinical Services 

Center Point Clinical Services LLC is a specialty contract research organization (CRO) that helps pharmaceutical and medical device companies successfully reach their regulatory and commercialization goals in less time and at a lower cost than competitors. The company offers two premier signature solutions. The first is the Clinical Trials Research Pharmacist (CTRP^®) program, which uses licensed, specially trained pharmacists to communicate with patients.  Center Point is the only CRO to offer such a unique and effective service. CTRP has repeatedly demonstrated improved patient retention, medication compliance and overall outcomes in clinical trials.  The second solution includes a series of practical study solutions intended to support regulatory and commercialization goals. These include: real-world evidence (RWE) analyses and publications, health economic outcomes and research (HEOR), market access and reimbursement support, industry standard quality metrics data, and scientific publications.

Visit our new website: http://www.centerpointclinicalservices.com

Like us on Facebook.

Follow us on Twitter and LinkedIn

Press Contact:
Marjie Hadad
MH Communications
+1-844-287-2877 Ext 9
[email protected]

SOURCE Center Point Clinical Services LLC